Raymond James Keeps a Buy Rating on Juno Therapeutics

By Ryan Adsit

Raymond James analyst Reni Benjamin maintained a Buy rating on Juno Therapeutics (NASDAQ: JUNO) yesterday. The company’s shares closed yesterday at $50.24.

Benjamin observed:

“Recommendation: We are maintaining our Outperform rating for JUNO. At the 2017 American Society of Hematology (ASH) meeting, Juno had multiple presentations featuring JCAR017 (a CD19 CAR T) as well as JCARH125 (an anti-BCMA CAR for multiple myeloma (MM). Key highlights include: 1) with more patients and a longer follow-up, JCAR017 appears to maintain a better safety profile in relapsed/refractory (R/R) aggressive Non-Hodgkin Lymphoma (NHL) as compared to Novartis’ Kymriah and Gilead’s Yescarta; 2) the safety profile of JCAR017 (1% grade ≥3 CRS and 15% grade ≥ 3 neurotoxicity (NT)) suggests that this CAR T therapy could be utilized in an outpatient setting; 3) JCARH125 has showcased an encouraging preclinical anti- tumor activity with initiation of Phase I study for MM expected in 1Q18.”

According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -8.8% and a 34.2% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Invivo Therapeutics Holdings, Sciclone Pharmaceuticals.

Juno Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $54.57.

The company has a one-year high of $63.45 and a one-year low of $17.52. Currently, Juno Therapeutics has an average volume of 2.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T.